Perrigo Settles Generic Rogaine Lawsuit

Allegan-based Perrigo Co. (Nasdaq: PRGO) Thursday announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by Stiefel Research Australia Pty. Ltd. Under the terms of the settlement, Perrigo can launch in the United States a generic version of Men's Rogaine Foam on March 1, 2012, or earlier under certain circumstances.

Rogaine (Minoxidil) Foam is used to regrow hair on the top of the scalp, and has annual sales of approximately $60 million, according to Information Resources Inc.  

"This is another example of Perrigo's commitment to bring products to market," Perrigo chairman and CEO Joseph C. Papa said. "Perrigo continues its focus on bringing quality, affordable healthcare to consumers."

Perrigo develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. Perrigo's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia.

More at www.perrigo.com.